Trials
(Mar 2021)
Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial
Iwein Gyselinck,
Laurens Liesenborghs,
Ewout Landeloos,
Ann Belmans,
Geert Verbeke,
Peter Verhamme,
Robin Vos,
W. Janssens,
on behalf of the DAWn-Azithro consortium
Affiliations
Iwein Gyselinck
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Laurens Liesenborghs
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Ewout Landeloos
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Ann Belmans
Interuniversity Institute for Biostatistics and Statistical Bioinformatics
Geert Verbeke
Interuniversity Institute for Biostatistics and Statistical Bioinformatics
Peter Verhamme
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Robin Vos
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
W. Janssens
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
on behalf of the DAWn-Azithro consortium
DOI
https://doi.org/10.1186/s13063-021-05153-4
Journal volume & issue
Vol. 22,
no. 1
Abstract
Read online
An amendment to this paper has been published and can be accessed via the original article.
WeChat QR code
Close
